Pseudoxanthoma elasticum (PXE), a multisystem heritable disorder with aberrant mineralization of arterial blood vessels, is caused by mutations in the ABCC6 gene. Previous studies have suggested that carriers of the ABCC6 mutations, particularly of p.R1141X, are at increased risk for coronary artery disease. In this study, we used Abcc6 tm1Jfk knock-out mice to determine the serum lipid profiles and examine the effects of atorvastatin on the aberrant mineralization in this model of PXE. First, serum lipid profiles at 12 weeks of age, after overnight fasting, revealed a statistically significant increase in total cholesterol and triglyceride levels in Abcc6 tm1Jfk mice compared to their wildtype littermates. Placing these mice at 4 weeks of age for 20 weeks on atorvastatin, either 0.01 % or 0.04 % of the diet (low statin and high statin groups, respectively), reduced the total triglyceride and cholesterol levels, which was accompanied with significantly reduced mineralization of the dermal sheath of vibrissae, a biomarker of the aberrant mineralization process in these mice. However, if the mice were placed on atorvastatin for 12 weeks at 12 weeks of age, at which time point significant mineralization had already taken place, no difference in the amount of mineralization was noted. These observations suggest that statins, particularly atorvastatin, can prevent, but not reverse, aberrant mineralization in this mouse model of PXE. For a clinical perspective, a survey of 1,747 patients with PXE was conducted regarding their present or past use of statins. The results indicated that about one third of all PXE patients are currently or have previously been on cholesterol-lowering drugs. Thus, a sizable number of patients with PXE could be subject to modulation of their mineralization processes by concomitant statin treatment.
Introduction
Aberrant deposition of calcium phosphate complexes in connective tissues is linked to a number of pathological conditions in the skin and vascular connective tissues [1, 2] . For example, the risk of death associated with coronary artery calcification in a cohort of over 25,000 patients was found to be increased by up to 12.5-fold [3] . Multiple factors, both genetic and environmental, can contribute to the pathomechanisms of both metastatic and dystrophic calcification [4, 5] . Significant insight into such factors has been gained by examination of Mendelian genetic disorders with aberrant mineralization of soft connective tissues, with accompanying animal models [6] . The prototype of heritable multisystem ectopic mineralization disorders is pseudoxanthoma elasticum (PXE), with calcium deposition in multiple tissues leading to protean clinical manifestations in the skin, the arterial blood vessels, and the eyes [7, 8] . PXE is, in most cases, caused by mutations in the ABCC6 gene which encodes a putative transmembrane transporter protein, ABCC6. Our understanding of the clinical features and pathomechanistic details of this disorder has been advanced by the study of Abcc6 −/− knock-out mice which recapitulate the features of PXE, including extensive mineralization in the arterial blood vessels, skin, and the Bruch's membrane in the eye [9, 10] . PXE has been suggested to be a metabolic disorder in which the nonfunctional ABCC6 transporter results in deficiency of anti-mineralization factor(s) in circulation, thus allowing calcium and phosphate to precipitate under physiologic conditions resulting in hydroxyapatite formation. However, the details of the chemical nature of such anti-mineralization factor(s) remain unknown [11] . PXE is inherited in an autosomal recessive pattern and the heterozygous carriers of the mutations in the ABCC6 gene do not demonstrate overt clinical findings [12] . However, it has been suggested that heterozygous carrier status of loss-of-function mutations in the ABCC6 gene, particularly that of p.R1141X, the most common mutation in the Caucasian populations, is associated with a strong increase in the prevalence of coronary artery disease [13, 14] . Thus, these mutations serve as a genetic risk factor in these individuals who do not have the PXE phenotype [12] .
In this study, we have used the Abcc6 tm1Jfk knock-out mouse [10] as a platform to examine the lipid profile in these mice and to test the hypothesis that statins, and specifically atorvastatin, a common cholesterol-lowering drug in clinical use, counteract tissue mineralization in this mouse model of PXE. The mice were placed on atorvastatin-containing diets at 4 weeks of age and followed for another 20 weeks (Prevention) or at 12 weeks of age followed by another 12 weeks (Reversal). The mice were sacrificed at the age of 24 weeks and compared with control mice, either Abcc6
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or Abcc6 −/− , maintained on normal diet levels. All mice were euthanized at 24 weeks of age and necropsied for tissue analysis.
Measurement of lipids
Total cholesterol and triglyceride levels in serum samples were determined by colorimetric assays. A modified Trinder method was performed to measure total cholesterol content (Cholesterol LiquiColor® Test (Enzymatic); Stanbio Laboratory, Boerne, TX). A glycerylphosphate oxidase method was performed to measure triglyceride content (Triglyceride LiquiColor® Test (Mono); Stanbio Laboratory). To measure total cholesterol and triglycerides, a Bio-Rad Model 680 microplate reader (Hercules, CA) was used to obtain absorbance values of samples at wavelength of 490 nm.
Histopathological analysis
Necropsy tissue samples from muzzle skin containing vibrissae and internal organs were fixed in 10 % phosphatebuffered formalin, processed routinely, and embedded in paraffin. The tissues were sectioned (6 μm) and stained with hematoxylin and eosin (HE) or Alizarin Red (AR) using standard procedures. Slides were examined for mineralization under light microscope.
Quantitation of tissue mineralization by computerized morphometric analysis
Computerized morphometric analysis of mineralization was performed on HE-stained sections with a Nikon Te2000 microscope furnished with an Auto Quant Imaging system (Watervliet, New York, NY). The degree of mineralization in vibrissae was expressed as a percentage of the total area of vibrissae per mouse, and the average percentage of mineralization was determined for each group [15] . All images were analyzed with Image-Pro software (Media Cybernetics, Rockville, MD).
Chemical quantification of calcium and phosphate
To quantify mineral deposition, muzzle skin was harvested and decalcified with 0.15 N HCl for 48 h at room temperature, followed by assay of calcium in the supernatant. Calcium and phosphate levels in serum samples were also determined. Colorimetric analysis by the o-cresolphthalein complexone method (Calcium (CPC) Liquicolor; Stanbio Laboratory, Boerne, TX) was performed to measure the calcium content. Phosphate content was determined with the Malachite Green Phosphate Assay kit (BioAssay Systems, Hayward, CA). Values for muzzle skin were normalized to tissue weight.
Statistical analysis
The comparisons between different groups of mice were completed using the two-sided Kruskal-Wallis nonparametric test, comparable to one-way analysis of variance, but without the parametric assumptions. Fisher's exact test was used to determine the difference between proportions of mineralization in organs of mice fed with different diets. All statistical computations were completed using SPSS version 15.0 software (SPSS Inc., Chicago, IL).
Clinical survey
Patients in the PXE International Patient Registry were contacted by e-mail and queried about their present or past treatment with cholesterol-lowering drugs, particularly statins. This study was approved by the Genetic Alliance Institutional Review Board.
Results
Abcc6
−/− mouse model for PXE Targeted ablation of the Abcc6 −/− mice results in aberrant mineralization of soft connective tissues [9, 10] . The first site of mineralization noted at ∼5-6 weeks of age of mice kept on normal laboratory diet is the dermal sheath of vibrissae in the muzzle skin (Fig. 1) . The mineralization of the vibrissae serves as an early biomarker of the mineralization process, and its quantitation either by histopathologic stains coupled with computerized morphometric analysis or by direct calcium assay of the muzzle skin containing the vibrissae allows monitoring of the overall progression of the mineralization in these PXE mice without sacrificing the animals [15] .
Serum lipid profile in Abcc6 −/− mice Serum lipid measurements at 12 weeks of age, after overnight fasting, demonstrated a statistically significant increase in serum concentrations of total cholesterol and triglycerides in Abcc6 −/− mice in comparison to wild-type littermates serving as controls (Fig. 2) . The efficacy of atorvastatin, an HMG-CoA reductase inhibitor, to lower the cholesterol and triglyceride levels and possibly alter the degree of mineralization was tested in subgroups of Abcc6 −/− mice in two experimental designs.
First, the Prevention Study consisted of Abcc6 −/− mice on normal diet (control, group B) and mice for whom the diet was supplemented with 0.01 % (low statin, group C) or 0.04 % (high statin, group D) of atorvastatin. These mice were followed for 20 weeks, measuring serum lipids every 4 weeks and then necropsied at 24 weeks to determine the degree of tissue mineralization. Feeding the 4-week-old mice with atorvastatin in the high statin group resulted in rapid and significant (47.8 %) decrease of triglycerides after 4 weeks on this diet, and the triglyceride levels remained low throughout the study (Fig. 3b ). The total serum cholesterol level was not statistically reduced until at 16 weeks on this diet, the reduction being 26.6 % compared to control mice on statin-free diet (group B) (Fig. 3a) .
Effects of atorvastatin on tissue mineralization in Abcc6
−/− mice Assay of mineralization in mice in the prevention study by computerized morphometric analysis of the dermal sheath of vibrissae or the content of calcium in the muzzle skin demonstrated a significant 26.9 % decrease in mice kept on high statin diet (group D), while the lower amount of statin did not alter the degree of mineralization in comparison to the normal diet (Fig. 4) . Thus, significant reduction in serum total cholesterol and triglyceride levels in these mice was accompanied by a reduced mineralization of the dermal sheath of vibrissae. These results suggested that statins, particularly atorvastatin, in relatively high daily quantities, are able to counteract the progression of mineralization in soft connective tissue in the skin. This study was extended to an experiment to determine whether the mineralization, once established, could be reversed by feeding the Abcc6 −/− mice with statins, again in low (group E) and high (group F) concentrations, in comparison to mice kept on normal diet without statin (group B). These mice were first kept on control diet for 12 weeks, and at this point at which significant mineralization had already taken place, the mice were placed on statin-containing diets for an additional 12 weeks. Assay of total cholesterol at 24 weeks of age revealed 18.4 % and 20.4 % reduction in groups E and F, respectively, but this change was not statistically significant (P>0.05; n=6-9). However, by as early as 4 weeks, the triglyceride values were reduced in group F by 71.8 % (P<0.01 in group F vs. group B or E). Assay of the degree of mineralization either by computerized morphometric analysis of histopathologic sections from the muzzle skin or by direct calcium chemical assay revealed no difference in the degree of mineralization between groups B, E, and F, suggesting that once the mineralization has taken place, the mineral content is not reduced by treatment by atorvastatin, but the deposition of new calcium phosphate complexes is inhibited (Fig. 5) .
In addition to mineralization of the dermal sheath of vibrissae in the skin, mineralization was examined in the kidneys, the heart, and the eyes by histopathological analysis by counting the number of mice that demonstrated mineralization as a percent of the total (n=6-10) ( Table 2) . No statistically significant differences were noted in the relative number of tissues involved in these mice.
Assay of serum calcium and phosphate did not demonstrate significant changes at the time of the sacrifice of the mice (Table 3) . Finally, the mean body weight of the Abcc6 −/− mice was not affected by the inclusion of statin into their diets, the mean body weight (grams) being 27.3±1.1, 26.6±1.1, 27.5±0.9, 24.8±1.3, and 23.6±0.9 in groups B, C, D, E, and F, respectively.
Clinical survey
To explore the clinical perspective of the potential importance of statins in patients with PXE, 1,747 patients in the PXE International Patient Registry, which consists of a total of ∼4,000 patients, for whom an e-mail address was available, were contacted regarding present or past use of statins. Of the total of 539 respondents, 24.1 % reported current and 6.7 % reported previous use of cholesterol-lowering drugs. Thus, a sizable number of patients with PXE is potentially subject to modulation of their mineralization processes by concomitant statin treatment for cholesterol-lowering purposes. 
Discussion
This study demonstrates that atorvastatin, a commonly prescribed cholesterol-lowering drug, can result in reduced mineral deposition of soft connective tissues in the skin of Abcc6 −/− mice, an animal model of PXE, a multisystem mineralization disorder. The reduced mineral deposition with atorvastatin, particularly in higher doses, was associated with reduced total cholesterol and triglyceride serum concentrations. Statins have previously been shown to affect mineralization processes, particularly in the context of bone metabolism [16] [17] [18] . With respect to these effects, statins have been suggested to augment the expression of bone morphogenic protein-2, a potent stimulator of osteoblast differentiation, and to promote mineralization by activated osteoblasts. This effect has been suggested to result from reduced protein prenylation, particularly of RhoA, a GTPbinding protein. Reduced prenylation of RhoA is postulated to result in increased activity of BMP-2 resulting in increased vascular endothelial growth factor activity and angiogenesis coupled with osteoblast differentiation and bone formation [19] . At the same time, statins have been reported to inhibit bone formation and produce a net reduction in bone density in rats, concluding that statins do not have in vivo anabolic effects on bone in rodents [20] . While the mineral deposits in soft tissues of Abcc6 −/− mice have been shown to consist of calcium hydroxyapatite [21, 22] , the pathomechanistic pathways resulting in aberrant mineral deposits are currently unknown. Thus, it is not clear how statins might elicit reduction of mineral deposition in these mice and whether the effect is related to the inhibition of the cholesterol pathway. It should be noted that the dosages of atorvastatin used in our study, selected on the basis of previous mouse studies reported in the literature with documented cholesterol-lowing effect [23, 24] , are high in comparison to clinical use in humans. The lower concentration of atorvastatin, 0.01 % of the diet, corresponds to a dietary dose of about 110 mg of atorvastatin for a 70 kg human adult, with the assumption that a mouse weighs about 25 g and eats about 5 g of food daily. It should be noted, however, that even the higher dose appeared not to be toxic to the mice, as their weight gain during the 24-week experimental study was not different from the mice on control diet, and the serum calcium and phosphate levels were essentially unchanged. It was of interest to note that the Abcc6 tm1Jfk knock-out mice at 12 weeks of age kept on normal laboratory diet showed increased total cholesterol and triglyceride levels. These observations differ from those reported by Gorgels et al. [9] on Abcc6 tm1Aabb knock-out mice, who noted somewhat decreased serum total cholesterol levels in 8-month-old mice as compared to the corresponding wild-type mice [9] . However, the total cholesterol and triglyceride values at 2.5-month-old mice were not different in their study. The possible reasons for the differences include different mouse diets and different genetic backgrounds, the mice in our study being congenic on 129S1/SvlmJ background [10] while the Abcc6 tm1Aabb mice developed by Gorgels et al. [9] were on C57BL/6 background. In summary, the results of the present study indicate that atorvastatin at a relatively high daily dose is able to prevent, but not to reverse, ectopic mineralization of soft connective tissues in Abcc6 −/− mice, a model for PXE. A clinical survey conducted by querying a group of patients with PXE in the Registry of the patient advocacy organization, PXE International, revealed that about one third of them were currently or had history of being treated with cholesterollowering drugs. Thus, a substantial number of PXE patients are subject to modulation of the mineralization process by statins, with potentially beneficial consequences.
